Patents Assigned to Institute of Pharmacology and Toxicology
-
Patent number: 10160767Abstract: The present invention pertains to the field of pharmaceutical chemicals, and relates to a rapamycin derivative of Formula I, and a preparation method, pharmaceutical composition and use thereof. The compounds of the present invention overcome the defects of rapamycin in terms of water solubility and metabolic properties, and some of the compounds have an in vitro anti-tumor activity superior to rapamycin, have less toxicity to normal cells than rapamycin, and have very good druggability.Type: GrantFiled: June 3, 2015Date of Patent: December 25, 2018Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Wu Zhong, Song Li, Shuang Cao, Ruiyuan Cao, Junhai Xiao, Xinbo Zhou, Xingzhou Li
-
Patent number: 10131643Abstract: The invention relates to a tizoxanide carbamate compound of Formula I and a pharmaceutically acceptable salt, a hydrate or a solvate thereof, and their pharmaceutical use.Type: GrantFiled: July 4, 2014Date of Patent: November 20, 2018Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Xingzhou Li, Wu Zhong, Zhibing Zheng, Junhai Xiao, Xinbo Zhou, Yunde Xie, Xiaokui Wang, Lili Wang, Wei Chen, Fei Xie
-
Patent number: 10071994Abstract: The invention relates to a homoserine lactone derivative of Formula I, preparation method and use thereof.Type: GrantFiled: May 25, 2015Date of Patent: September 11, 2018Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Junhai Xiao, Qi Sun, Wu Zhong, Lili Wang, Zhibing Zheng, Yunde Xie, Xingzhou Li, Xinbo Zhou, Xiaokui Wang, Ruiyuan Cao
-
Patent number: 10023565Abstract: The present invention relates to a compound of formula (I), a stereomeride, pharmaceutically acceptable salt, a solvate or an N-oxide thereof, a medicine composition comprising the compound, a method for preparing the compound, and a usage of the compound in treating diseases related to Hsp70. The diseases are preferably selected from tumors, neurodegenerative diseases, and allogeneic transplantation rejection and infection.Type: GrantFiled: December 19, 2014Date of Patent: July 17, 2018Assignee: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINAInventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang, Lili Wang
-
Publication number: 20180185376Abstract: The invention belongs to the technical field of medicines. In particular, the invention relates to a thiazideamide derivative compound or a pharmaceutically acceptable salt or solvate thereof, a pharmaceutical composition comprising the compound or a pharmaceutically acceptable salt or solvate thereof, a method for preparing the compound or a pharmaceutically acceptable salt or solvate thereof, and a use of the compound or a pharmaceutically acceptable salt or solvate thereof. For example, the compound or a pharmaceutically acceptable salt or solvate thereof according to the invention can be used to prevent and/or treat a neurodegenerative disease or a neuropathic disease caused by a physical trauma or a related disease.Type: ApplicationFiled: June 28, 2016Publication date: July 5, 2018Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Junhai XIAO, Boqun LYU, Hongqiang WANG, Wu ZHONG, Lili WANG, Zhibing ZHENG, Yunde XIE, Xinbo ZHOU, Xingzhou LI, Xiaokui WANG
-
Publication number: 20180179193Abstract: The invention relates to a homoserine lactone derivative of Formula I, preparation method and use thereof. The compound has an effect of regulatory of bacterial quorum sensing, and is useful for preventing and/or treating a disease caused by infection of a bacterium.Type: ApplicationFiled: May 25, 2015Publication date: June 28, 2018Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Junhai XIAO, Qi SUN, Wu ZHONG, Lili WANG, Zhibing ZHENG, Yunde XIE, Xingzhou Li, Xinbo ZHOU, Xiaokui WANG, Ruiyuan CAO
-
Publication number: 20180134653Abstract: The present invention pertains to the field of pharmaceutical chemicals, and relates to a substituted acethydrazide derivative, preparation method and use thereof; preferably, relates to a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention or a pharmaceutically acceptable salt thereof can effectively inhibit proline hydroxylase, stabilize HIF-?, particularly HIF-1?, and has potency in the manufacture of a medicament for treatment and/or prophylaxis and/or adjuvant therapy of anemia, acute ischemic reperfusion injury.Type: ApplicationFiled: November 20, 2017Publication date: May 17, 2018Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Junhai XIAO, Lili WANG, Long LONG, Wei LI, Haoming LUO, Feifei LI, Wu ZHONG, Zhibing ZHENG, Yunde XIE, Xingzhou LI, Xinbo ZHOU, Xiaokui WANG, Ruiyuan CAO
-
Patent number: 9914711Abstract: The invention relates to a compound of formula I, and a preparation method and use thereof. The compound has a bacterial quorum-sensing regulatory effect, and can be used for prevention and/or treatment of a disease caused by a bacterial infection.Type: GrantFiled: December 10, 2013Date of Patent: March 13, 2018Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Junhai Xiao, Mingming Zhao, Wu Zhong, Lili Wang, Zhibing Zheng, Yunde Xie, Xingzhou Li, Guoming Zhao, Xinbo Zhou, Xiaokui Wang, Wei Chen
-
Publication number: 20180044321Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.Type: ApplicationFiled: October 26, 2017Publication date: February 15, 2018Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Wu ZHONG, Song LI, Yanqun ZENG, Junhai XIAO, Xinbo ZHOU, Zhibing ZHENG, Xingzhou LI, Xiaokui WANG
-
Publication number: 20170362261Abstract: The invention relates to tizoxanide phosphate or alkane sulfonate compounds represented by Formula I, and pharmaceutically acceptable salts thereof, isomers thereof, hydrates thereof or solvates thereof, and pharmaceutical applications of the compounds.Type: ApplicationFiled: December 11, 2015Publication date: December 21, 2017Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song LI, Xingzhou LI, Wu ZHONG, Zhibing ZHENG, Junhai XIAO, Xinbo ZHOU, Yunde XIE, Xiaokui WANG, Lili WANG, Wei CHEN, Fei XIE
-
Patent number: 9840489Abstract: The present invention provides a compound of a general formula I, a stereomeride, pharmaceutically acceptable salt or a solvate thereof, a preparation method thereof, and usages in preparing medicines for preventing and/or treating diseases or symptoms caused by drug-resistant tumors or drug-resistant bacteria and in preparing medicines for preventing and/or treating diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection. Preferably, the diseases or symptoms related to tumors, neurodegenerative diseases, allogeneic transplantation rejection, and infection are diseases or symptoms caused by a heat shock protein 70 (Hsp70). The compound in the present invention is used for overcoming a difficult problem of drug resistance of tumors, improves the effect of tumor treatment, and provides a new medical strategy for clinical tumor treatment.Type: GrantFiled: December 19, 2014Date of Patent: December 12, 2017Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
-
Publication number: 20170253606Abstract: The present invention pertains to the field of pharmaceutical chemicals, and relates to a rapamycin derivative of Formula I, and a preparation method, pharmaceutical composition and use thereof. The compounds of the present invention overcome the defects of rapamycin in terms of water solubility and metabolic properties, and some of the compounds have an in vitro anti-tumor activity superior to rapamycin, have less toxicity to normal cells than rapamycin, and have very good druggability.Type: ApplicationFiled: June 3, 2015Publication date: September 7, 2017Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Wu ZHONG, Song LI, Shuang CAO, Ruiyuan CAO, Junhai XIAO, Xinbo ZHOU, Xingzhou LI
-
Patent number: 9751884Abstract: The present invention relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, its preparation method, a pharmaceutical composition comprising the compound, and its use in manufacture of a medicament for treatment of a disease or disorder, wherein R1, R2, R5, R6, X, Y, Q, W, n1 and n2 are defined as those stated in the description.Type: GrantFiled: May 30, 2013Date of Patent: September 5, 2017Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Lan Xie, Xiaofeng Wang, Kuo-Hsiung Lee
-
Patent number: 9750841Abstract: A medical adhesive with good biodegradable performance capable of undergoing crosslinking copolymerization, comprising a mono-alpha-cyanoacrylate and a bis-alpha-cyanoacrylic acid diol ester monomer molecule. The olefinic bonds in the mono-alpha-cyanoacrylate structure are polymerized in the presence of infinitesimal anions to form a solid 3D high polymer; the 3D high polymer is provided with degradation sites on the web-like backbone chain, with clear degradation path and absorbable degradation products. The medical adhesive can be used for wound adhesive, large area wound hemostasia, and visceral and soft tissue wound closure.Type: GrantFiled: October 31, 2012Date of Patent: September 5, 2017Assignees: INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A., CHENGDU YIPING MEDICAL SCIENCE & TECHNOLOGY CO. LTDInventors: Keliang Liu, Liang Xu, Qingsong Zhang, Dazhen Cai, Qingbin Meng
-
Publication number: 20170224840Abstract: The present invention relates to a drug delivery system, comprising: a drug-loaded carbon nanotube formed by a carbon nanotube and a drug molecule adsorbed on the surface of the carbon nanotube, a modifying material capable of enhancing water solubility and biocompatibility of the drug delivery system, and a targeting molecule. The present invention further relates to preparation and use of the drug delivery system. The present invention provides a new strategy for selectively targeting and effectively eliminating cancer stem cells, which is conducive to fundamentally preventing recurrence and metastasis of a cancer induced by cancer stem cells.Type: ApplicationFiled: August 11, 2015Publication date: August 10, 2017Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Hongjuan YAO, Yingge ZHANG, Lan SUN, Yan LIU
-
Patent number: 9718770Abstract: The invention provides a compound of Formula I, an isomer, a pharmaceutically acceptable salt, or a solvate thereof, and use thereof in manufacture of a medicament for preventing and/or treating a drug-resistant tumor or disease or disorder caused by a drug-resistant bacterium, or use thereof in manufacture of a medicament for preventing and/or treating a tumor, a neurodegenerative disease, an allogeneic graft rejection, or an infection-associated disease or disorder; preferably, the tumor, neurodegenerative disease, allogeneic graft rejection, or infection-associated disease or disorder is a disease or disorder caused by Heat shock protein 70 (Hsp70). The compounds of the invention, which are a class of Hsp70 inhibitors having a novel structure and a high activity, solve the problem concerning drug resistance of tumors, enhance the effect of treating tumors, and provide a new medical strategy for treatment of tumors in clinic.Type: GrantFiled: December 18, 2014Date of Patent: August 1, 2017Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Wu Zhong, Song Li, Yanqun Zeng, Junhai Xiao, Xinbo Zhou, Zhibing Zheng, Xingzhou Li, Xiaokui Wang
-
Publication number: 20170190656Abstract: The present invention pertains to the field of pharmaceutical chemicals, and relates to a substituted acethydrazide derivative, preparation method and use thereof; preferably, relates to a compound of Formula I or a pharmaceutically acceptable salt thereof. The compound of the present invention or a pharmaceutically acceptable salt thereof can effectively inhibit proline hydroxylase, stabilize HIF-?, particularly HIF-1?, and has potency in the manufacture of a medicament for treatment and/or prophylaxis and/or adjuvant therapy of anemia, acute ischemic reperfusion injury.Type: ApplicationFiled: May 20, 2015Publication date: July 6, 2017Applicant: Institute of Pharmacology and Toxicology Academy of Millitary Medical Sciences P.L.A. ChinaInventors: Song LI, Junhai XIAO, Lili WANG, Long LONG, Wei LI, Haoming LUO, Feifei LI, Wu ZHONG, Zhibing ZHENG, Yunde XIE, Xingzhou LI, Xinbo ZHOU, Xiaokui WANG, Ruiyuan CAO
-
Patent number: 9683988Abstract: The present invention provides a cell model and a method for screening c-Fms tyrosine kinase inhibitors. Specifically, the present invention provides a cell that expresses macrophage colony stimulating factor receptor and STAT1 protein simultaneously. The present invention further provides a method for screening c-Fms tyrosine kinase inhibitors, a method for evaluating the inhibiting activity of a compound or a composition against c-Fms tyrosine kinase, and use of the cell in screening c-Fms tyrosine kinase inhibitors. The cell model established in the present invention is sensitive, highly effective and reliable, and can be used in high-throughput screening and/or high-content screening of c-Fms tyrosine kinase inhibitors.Type: GrantFiled: March 14, 2012Date of Patent: June 20, 2017Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Lili Wang, Shengqian Yang, Long Long, Junhai Xiao, Song Li
-
Publication number: 20170119701Abstract: The invention relates to a drug sustained-release composition, particularly a sustained-release composition comprising metoprolol and preparation method thereof. The invention also relates to a combination product comprising a sustained-release composition comprising metoprolol and a pharmaceutical composition comprising hydrochlorothiazide. The sustained-release composition comprising metoprolol according to the invention eliminates the phenomena of delayed release of such sustained-release compositions in the prior art, has a better drug release curve, and also have the advantages such as simple formula, easy operation, stable quality, strong controllability, and good reproducibility, and therefore have good application prospects.Type: ApplicationFiled: June 23, 2015Publication date: May 4, 2017Applicant: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Chunsheng GAO, Yuli WANG, Meiyan YANG, Li SHAN, Jingjing DAI, Yong QIAN, Yan QIU
-
Patent number: 9630957Abstract: Provided are a compound of formula I which can be used as a drug against small RNA virus infections, and optical isomers, pharmaceutically acceptable salts, solvates or hydrates thereof. Also provided are the preparation method of the compound, the method for using the compound for treating bacterial infections and the use of the compound in the preparation of a drug for preventing and/or treating viral diseases caused by small RNA viruses.Type: GrantFiled: May 28, 2014Date of Patent: April 25, 2017Assignee: Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. ChinaInventors: Song Li, Junhai Xiao, Xian Zhang, Wu Zhong, Zhibing Zheng, Lili Wang, Yunde Xie, Xingzhou Li, Xinbo Zhou, Xiaokui Wang